Literature DB >> 15775780

Influence of the endothelial nitric oxide synthase gene on conventional and ambulatory blood pressure: sib-pair analysis and haplotype study.

Alexandre Persu1, Wouter J Vinck, Ouarda El Khattabi, Rob G J H Janssen, Aimée D C Paulussen, Olivier Devuyst, Robert Vlietinck, Robert H Fagard.   

Abstract

BACKGROUND: Nitric oxide is involved in the regulation of vascular basal tone and blood pressure. Polymorphisms of NOS3, the gene that codes for endothelial nitric oxide synthase, have been associated with essential hypertension.
OBJECTIVE: To look for linkage and association of three di-allelic polymorphisms (Glu298Asp, intron 4 VNTR and T-786C) and the intron 13 CA-repeat of NOS3 with blood pressure as a continuous trait.
METHODS: Genotyping was performed in 110 dizygotic white twin pairs from Flanders, Belgium. The influence of NOS3 polymorphisms on conventional and ambulatory blood pressure was assessed by sib-pair analysis and haplotype association analysis.
RESULTS: Genotype frequencies were similar to those previously reported in white populations. Sib-pair analysis did not show a significant influence of either polymorphism on blood pressure. Haplotype analysis disclosed a significant association between NOS3 haplotypes and daytime ambulatory diastolic (P = 0.02) and systolic (P < 0.0001) blood pressure, the latter remaining significant after multiple testing was taken into account (P = 0.032). The association between daytime ambulatory systolic blood pressure and NOS3 haplotypes was mainly attributable to four haplotypes accounting for 11.9% of all represented haplotypes.
CONCLUSION: We show for the first time a highly significant association of ambulatory blood pressure with NOS3 haplotypes in well-characterized white individuals from Flanders. These results pave the way for studies looking for the influence of NOS3 on blood pressure in high-risk subsets such as diabetic or hypertensive patients. They indicate the importance of ambulatory blood pressure and haplotype analysis in revealing the moderate effect of polymorphisms on blood pressure.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15775780     DOI: 10.1097/01.hjh.0000163144.74588.ad

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  6 in total

Review 1.  Nitrates as adjunct hypertensive treatment.

Authors:  Gordon S Stokes
Journal:  Curr Hypertens Rep       Date:  2006-04       Impact factor: 5.369

2.  Association of renin-angiotensin and endothelial nitric oxide synthase gene polymorphisms with blood pressure progression and incident hypertension: prospective cohort study.

Authors:  David Conen; Robert J Glynn; Julie E Buring; Paul M Ridker; Robert Y L Zee
Journal:  J Hypertens       Date:  2008-09       Impact factor: 4.844

3.  Association of polymorphisms in NOS3 with the ankle-brachial index in hypertensive adults.

Authors:  Iftikhar J Kullo; M Todd Greene; Eric Boerwinkle; Jian Chu; Stephen T Turner; Sharon L R Kardia
Journal:  Atherosclerosis       Date:  2007-03-23       Impact factor: 5.162

4.  Negative association of endothelial nitric oxide gene polymorphism with hypertension in Turkish patients: effect of ecNOS polymorphism on left ventricular hypertrophy.

Authors:  Ayhan Olcay; C Gokhan Ekmekci; Ugur Ozbek; Murat Sezer; Cem Barcin; Erol Arslan; Bilal Boztosun; Yilmaz Nisanci
Journal:  Cardiovasc Ultrasound       Date:  2006-08-21       Impact factor: 2.062

5.  Role of endothelial nitric oxide synthase VNTR (intron 4 a/b) polymorphism on the progression of renal disease in autosomal dominant polycystic kidney disease.

Authors:  Ramprasad Elumalai; Soundararajan Periasamy; Gnanasambandan Ramanathan; Bhaskar Vks Lakkakula
Journal:  J Renal Inj Prev       Date:  2014-07-01

6.  Endothelial Nitric Oxide Synthase (eNOS) and the Cardiovascular System: in Physiology and in Disease States.

Authors:  N Tran; T Garcia; M Aniqa; S Ali; A Ally; S M Nauli
Journal:  Am J Biomed Sci Res       Date:  2022-01-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.